Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$9.61
-$0.70(-11.71%)
At close: 4:00 PM EST
$9.61
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $11.40
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.26M
Market Cap
$825.88M
Enterprise Value$469.68M
Total Cash (Recent Filing)$150.51M
Total Debt (Recent Filing)$41.87M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 19, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding88,804,350
10 Day Avg. Volume1,031,352
30 Day Avg. Volume1,262,950
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)4.05
P/FCF Ratio-7.33
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue6.80
Enterprise Value/Gross Profit25.49
Enterprise Value/Ebitda-7.38
Forecast
1Y Price Target
$11.17Price Target Upside16.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$83.54M
Bulls Say, Bears Say
Bulls Say
Commercial Adoption / PartnershipsCommercial partner Tempus is actively selling NeXT Personal, driving faster‑than‑anticipated test volume growth and supporting broader market adoption and revenue expansion.
Financing / Balance SheetLarge ATM cash raise materially de‑risked the company's balance sheet and enables a more aggressive commercial launch of NeXT Personal.
Reimbursement / CoverageMedicare coverage for NeXT Personal in breast cancer enables reimbursement for key tests and supports a ramp in clinical testing revenue that can help reduce cash burn.
Bears Say
Analyst Sentiment / Reporting UncertaintyAnalyst's intent to wait for full reported results before updating financial models indicates near‑term uncertainty and cautious investor sentiment.
Operational And Legal RisksCustomer concentration, legal and intellectual property exposure, intensifying competition, and existing financial vulnerabilities could negatively affect performance if any of these areas worsen.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $11.40 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $825.88M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Feb 19, 2026 which is in 34 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Nov 04, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.027.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.3.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,804,350 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -12.257%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.17 (16.23% Upside)
$11.17 (16.23% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $266.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.28%
12-Months-Change
Fundamentals
Return on Equity
-43.69%
Trailing 12-Months
Asset Growth
1.23%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical adoption and strategic partnerships, but also revealed significant revenue and margin challenges. While the company is confident in its clinical and reimbursement advancements, financial performance faced headwinds due to biopharma volatility and revenue declines.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$11.17
▲(16.23% Upside)
Technical Analysis
Ownership Overview
0.68% Insiders
8.66% Mutual Funds
0.09% Other Institutional Investors
74.20% Public Companies and
Individual Investors